Brind.
  1. Canaccord raised its price target for Illumina shares, noting that revenue growth driven by clinical customers and NovaSeq X adoption is key to expansion goals.

SomaLogic reported its revenue alongside NovaSeq X data.

1 report, 1 independent Updated Jul 30
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

SomaLogic reported its revenue alongside NovaSeq X data.

Who's involved

What this event is mainly about
SomaLogic

Keep exploring

Part of

Canaccord raised its price target for Illumina shares, noting that revenue growth driven by clinical customers and NovaSeq X adoption is key to expansion goals. All 1 developments

The entities involved

  • SomaLogic

    company in Boulder, United States

    Nothing else this week.

Coverage

Newest first; wire copies grouped